Targeting fatty acid synthase suppresses tumor development in NF2/CDKN2A-deficient malignant pleural mesothelioma
Karnan, S.; OTA, A.; Hasan, M. N.; Murakami, H.; Rahman, M. L.; Wahiduzzaman, M.; Shihan, M. T. A. S. T. A.; Jahan, N.; Vu, L. Q.; Hanamura, I.; Inoko, A.; Riku, M.; Ito, H.; Kaneko, Y.; Lin, Y.; Hyodo, T.; Konishi, H.; Tsuzuki, S.; Hosokawa, Y. H.
Show abstract
Malignant pleural mesothelioma (MPM) is an uncommon yet deadly cancer linked to asbestos exposure. The lack of effective early diagnosis and treatment leads to reduced life expectancy among patients with MPM. This study is aimed to identify a novel molecular target inhibitor to develop more effective therapeutics for MPM. Our drug screening assay showed that the fatty acid synthase (FASN) inhibitor cerulenin demonstrates strong and selective anti-proliferative properties against NF2/CDKN2A(p16)-deficient MPM cells, surpassing the effects of cisplatin or pemetrexed. FASN protein is frequently detected in NF2/p16-deficient MPM tumor-derived tissues (15/15, 100%), but rarely in NF2/p16-intact MPM tumors (8/25, 32%). Notably, cerulenin administration successfully reduced the growth of NF2/p16-deficient MPM tumors in xenografted mice. Cerulenin inhibits mitochondrial fission by targeting dynamin-related protein 1 (DRP1) in NF2/p16-deficient cells. Moreover, the disruption of the FASN gene leads to increased ubiquitination of DRP1. These findings suggest that FASN might play a role in the tumorigenesis of MPM cells through the regulation of mitochondrial dynamics. This research offers a novel perspective on the potential development of precision medicine for MPM.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Tumors cells with mismatch repair deficiency induce hyperactivation of Pyroptosis resistant to cell membrane damage but are more sensitive to Co-treatment of IFN-γ and TNF-α to PANoptosis 95%
- Effect of OASL on OXA-induced immunogenic cell death in gastric cancer via cGAS-STING pathway 94%
- Inhibiting BCKDK in triple-negative breast cancer suppress protein translation, impair mitochondrial function, and potentiate doxorubicin cytotoxicity 94%
Similar papers in this journal
- Branched chain amino acid aminotransferase 2 Regulates Ferroptotic Cell Death in Cancer Cells 95%
- Drug tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms 94%
- Distinct GSDMB protein isoforms and protease cleavage processes differentially control pyroptotic cell death and mitochondrial damage in cancer cells. 94%
Similar papers in this journal
- KRAS Inhibition Reverses Chemotherapy Resistance Promoted by Therapy-Induced Senescence-like in Pancreatic Ductal Adenocarcinoma 94%
- Chitinase 3-like-1 (CHI3L1) in the Pathogenesis of Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer 94%
- ORMDL1 is upregulated and associated with favorable outcome in colorectal cancer 94%
Similar papers in this journal
- The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinoma 95%
- Dysregulation of lncRNA MALAT1 Contributes to Lung Cancer in African Americans by modulating the tumor immune microenvironment 94%
- The defined TLR3 agonist, Nexavant, exhibits anti-cancer efficacy and potentiates anti-PD-1 antibody therapy by enhancing immune cell infiltration. 94%